Patents Examined by Sharon Turner
  • Patent number: 7214656
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: May 8, 2007
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Ellen Filvaroff, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Patent number: 7193074
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: March 20, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
  • Patent number: 7193045
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: December 26, 2001
    Date of Patent: March 20, 2007
    Assignee: Genetech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, James Pan, Colin K. Watanabe, William I. Wood
  • Patent number: 7189529
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: March 13, 2007
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Kevin P. Baker, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Ellen Filvaroff, Sherman Fong, Wei-Qiang Gao, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Ivar J. Kljavin, Sophia S. Kuo, Mary A. Napier, James Pan, Nicholas F. Paoni, Margaret Ann Roy, David L. Shelton, Timothy A. Stewart, Daniel Tumas, P. Mickey Williams, William I. Wood
  • Patent number: 7175988
    Abstract: The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.
    Type: Grant
    Filed: February 8, 2002
    Date of Patent: February 13, 2007
    Assignee: Human Genome Sciences, Inc.
    Inventors: Viktor Roschke, Craig A. Rosen, Steven M. Ruben
  • Patent number: 7169783
    Abstract: The invention relates to an antagonist of one or more of Rho family members having ability to elicit neurite outgrowth from cultured neurons in an assay method which includes culturing neurons on a substrate that incorporates a growth-inhibiting amount of Rho family member and exposing the cultured neurons to a candidate Rho family member antagonist agent to permit neuron growth. Candidates which elicit neurite outgrowth from the cultured neurons are thus identified as Rho family antagonists.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: January 30, 2007
    Assignee: Universite de Montreal
    Inventors: Lisa McKerracher, Maxime Lehmann
  • Patent number: 7160546
    Abstract: Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: January 9, 2007
    Assignee: Human Genome Sciences, Inc.
    Inventors: Yi Li, Steven M Ruben
  • Patent number: 7125687
    Abstract: The invention provides methods and compositions relating to pen polypeptides having pen-specific structure and activity, related polynucleotides and modulators of pen function. The invention provides isolated pen hybridization probes and primers capable of specifically hybridizing with natural pen genes, pen-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis (e.g. genetic hybridization screens for pen transcripts), therapy (e.g. pen inhibitors to modulate APP processing) and in the biopharmaceutical industry (e.g. as immunogens, reagents for screening chemical libraries for lead pharmacological agents, etc.).
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: October 24, 2006
    Assignee: Exelixis, Inc.
    Inventors: Daniel Tim Curtis, George Ross Francis, Michael Christopher Ellis, David Andrew Ruddy, Sharmon Monique Nicoll, Garth Joseph McGrath
  • Patent number: 7109319
    Abstract: The invention provides isolated nucleic acid molecules, designated FAIL, which encode polypeptide molecules containing Ig and Ig-like domains and which are homologous to Fc?RI. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: March 10, 2003
    Date of Patent: September 19, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Christopher C. Fraser
  • Patent number: 7105640
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: September 12, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Patent number: 7098304
    Abstract: The invention concerns peptides which bind antibodies that are found in elevated levels in body fluids of schizophrenic patients and are found at a lower level or not found at all in body fluids of non-schizophrenic individuals. Using a computerized program, the antigenic epitope of the peptides of the invention is predicted as having a core of hydrophobic amino acids which is surrounded by positively charged amino acids. The peptides of the invention are useful in the diagnosis of schizophrenia in an individual.
    Type: Grant
    Filed: March 30, 1999
    Date of Patent: August 29, 2006
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Meir Shinitzky, Michael Deckmann
  • Patent number: 7090985
    Abstract: The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam SV2 proteins, including SV2A.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: August 15, 2006
    Assignee: UCB, S.A.
    Inventors: Berkley Lynch, Karl Nocka, Bruno Fuks
  • Patent number: 7090987
    Abstract: The invention features methods of diagnosing and treating a patient having Alzheimer's disease or other neuronal atrophy-associated dementia by determining or altering, respectively, the level of activity of pathways from the endoplasmic reticulum to lysosomes in the patient.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: August 15, 2006
    Inventors: Ralph A. Nixon, Anne M. Cataldo, Paul M. Mathews
  • Patent number: RE46912
    Abstract: The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well. Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: June 26, 2018
    Assignee: BIONEER CORPORATION
    Inventors: Ji Hee Kang, Byeung I. You, Sung I. Yun, Han O. Park
  • Patent number: RE47123
    Abstract: Antagonistic antibodies that specifically bind to and inhibit Class A Eph receptors are provided. Also provided are cytotoxic conjugates, pharmaceutical compositions and kits comprising these antibodies.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: November 13, 2018
    Assignee: SANOFI
    Inventors: Veronique Blanc, Claudia Fromond, Fabienne Parker, Jiawen Han, Daniel Tavares, Chonghui Zhang, Min Li, Xiao-Mai Zhou, Michel Streuli
  • Patent number: RE47194
    Abstract: Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: Ab-(L-D)p ??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: January 8, 2019
    Assignee: Genentech, Inc.
    Inventors: Jagath R. Junutula, William Mallet
  • Patent number: RE47223
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: February 5, 2019
    Assignee: GENENTECH, INC.
    Inventors: Mark S. Dennis, Paul Polakis, William Mallet
  • Patent number: RE47300
    Abstract: This invention relates to anti-cancer compounds and to methods for treating or preventing cancer. In one aspect the invention concerns mitochondrially delivered pro-oxidant anti-cancer compounds that generate reactive oxygen species and induce apoptosis of cancerous cells. The delivery moiety can be a lipophilic cation and the pro-oxidant moiety can be a pro-oxidant vitamin E analogue, such as ?-tocopheryl succinate, ?-tocopheryl maleate, ?-tocopheryl maleyl amide, or 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)-chroman-6-yloxyacetic acid (?-tocopheryloxyacetic acid).
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: March 19, 2019
    Assignee: CANCURE LIMITED
    Inventors: Stephen John Ralph, Jiri Neuzil
  • Patent number: RE47826
    Abstract: The invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: January 28, 2020
    Assignee: INNOCOLL PHARMACEUTICALS LIMITED
    Inventors: Michael Myers, Philip Wallace Reginald
  • Patent number: RE48060
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of PTP1B mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: June 23, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Susan M. Freier